What else do you need to know about the COVID-19 vaccine and its impact on fertility?
Both the Pfizer and Moderna vaccines are messenger ribonucleic acid (mRNA)-based and therefore do not contain the live virus. This means that the vaccine elicits an immune response so if the recipient were to get COVID-19 she would have some immunity over it.
The vaccine does NOT appear to interfere with fertility in men or women.
Vios Fertility Institute is proud to partner with the University of California-San Francisco to make patients aware of the ASPIRE study regarding COVID19 and pregnancy. ASPIRE stands for Assessing Safety of Pregnancy In the Coronavirus Pandemic.
From ASPIRE, “The goal of this study is to help understand the spread of COVID-19 infection among pregnant women and how infection might affect the health and wellbeing of pregnant mothers and their babies, particularly when the infection occurs in early pregnancy or without any symptoms. The goal is for this knowledge to inform and empower pregnant women and their healthcare providers to provide the best possible care for their pregnancies and future babies. Also, women and couples planning pregnancies will gain important information to help make decisions for their families.”
ASPIRE is focused on the first trimester, a critical and vulnerable period when all of a baby’s organ systems form and the placenta – the crucial connection between mom and baby – develops.
Currently, there are no data about the effects of COVID19 infections in the first trimester. The ASPIRE study will provide critical information to:
(1) Guide the care of pregnant women
(2) Protect the safety of their babies and families
(3) Help those considering pregnancy in the future understand what it means to be pregnant in this new era
Becoming pregnant at any time is a personal choice and with the added uncertainty of a global pandemic, we realize this decision did not come lightly. We celebrate your pregnancy!
We’re also careful to counsel our patients at every step of their care journey about COVID19 and pregnancy considerations and safety guidelines so that you can feel informed and an active and empowered partner in your care.
Who can join the ASPIRE Study?
Anyone who is over the age of 18 and is between 4 – 10 weeks pregnant. Eligible participants will be compensated financially.
You’ll be asked to:
1. Submit frequent, quick (<1 minute each) symptom tracking reports using your mobile phone and/or computer.
2. Collect finger-stick blood samples from home at several points throughout your pregnancy. (A helpful how to video is here.)
3. Give permission to review medical records related to your pregnancy, delivery and baby’s development.
4. Complete questionnaires online about your health during your pregnancy and after delivery of your baby.
Miscarriage is a heartbreaking reality for many as they try to conceive and, sometimes, a woman can experience multiple miscarriages in a row.
Recurrent Pregnancy Loss (RPL) is defined by the American Society for Reproductive Medicine (ASRM) as two or more consecutive pregnancy losses. We know this is a heartbreaking loss and we are committed to helping our patients find answers and treatment options to help.
The first step is a series of diagnostic tests to understand what may be causing the miscarriages. There are some common causes of RPL including genetic, hormone imbalance, uterine abnormality, and undiagnosed medical conditions. Some reasons remain unknown despite the myriad of available testing options.
As fertility specialists, we’re asked a lot about ovarian health and ovarian reserve – specifically egg quantity and quality.
A woman is born with all the eggs she’ll ever have. At birth, a baby girl typically has about 1 million eggs and by puberty this number has declined to 500,000. Each month, a handful of eggs are eligible to become mature but only one will be ovulated. (For a detailed description of this process, click here.)
Age is one of the most important factors in a woman’s fertility potential. Yet, there is no “magic” age and recent studies show that genetics and the environment also play an important role in egg and reproductive health.
CHICAGO, IL (August 12, 2019) —Known to many as the “world’s first test tube baby,” the UK’s Louise Brown is still making headlines some forty-one years later. But this time, it’s for her new role as a brand ambassador Vios Fertility Institute, one of the fastest growing fertility clinics in the U.S. (more…)
This wonderful, challenging, rewarding and at times heart breaking field of reproductive medicine is ever changing and expanding with new technologies, treatments, and techniques. All with the goal of welcoming new life into this world. To continue to innovate and push our field forward, it is important to look back at where we started and how far we have come.
Vios Fertility Institute – St. Louis Welcomes Two New Physicians to its Team of Fertility Experts
St. Louis, MO (August 1, 2019) — Doctors Amber Cooper, MD, MSCI, FACOG (medical and IVF practice director), and Julie Rhee, MD, FACOG of Vios Fertility Institute St. Louis are pleased to announce the addition of Violet Klenov, MD, FACOG, and MacKenzie Purdy, MD, FACOG to the team. Both women are fellowship-trained, board eligible reproductive endocrinologists and infertility specialists. (more…)
Article by: Lindsey Jacobson, ABC News, July 18, 2018
“Forty years after the first ever “test tube baby” Louise Joy Brown was born, 33 percent of American adults report using fertility treatment or knowing someone who used fertility treatment to have a baby, according to a new study.” Read the article here.